|

leucovorin Clinical Trials

56 actively recruiting trials across 27 locations

Also known as: Calcium Folinate, Calcium Leucovorin,, Calciumfolinat, Citrovorum Factor, Folinic Acid +7 more

Pipeline

Phase 1: 19Phase 2: 16Phase 3: 11Phase 1/2: 8Phase 2/3: 1

Top Sponsors

Merck Sharp & Dohme LLC4
Astellas Pharma Global Development, Inc.4
National Cancer Institute (NCI)3
AstraZeneca3
SWOG Cancer Research Network2

Indications

Cancer56
Gastric Cancer6
Gastroesophageal Junction Adenocarcinoma5
Pancreatic Ductal Adenocarcinoma5
Colorectal Cancer5

Other13 trials

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Phase 1/2

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Phase 1/2

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Phase 1/2

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

Phase 1

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Phase 2

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Phase 3

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Phase 3

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

Phase 3

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Phase 2

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Phase 2

Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-

N/A

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Phase 3

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

Phase 2/3

Birmingham, Alabama6 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 3

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

O Neal Comprehensive Cancer Center at UAB

Phase 1/2

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

University of Alabama at Birmingham

Phase 1

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

University of Alabama at Birmingham Cancer Center

Phase 3

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Duarte, California6 trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

City of Hope National Medical Center /ID# 270255

Phase 2

First in Human Study of AZD9592 in Solid Tumors

Research Site

Phase 1

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

City of Hope

Phase 1

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

City of Hope Medical Center

Phase 1

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Phoenix, Arizona3 trials

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Mayo Clinic Arizona

Phase 2

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Cancer Center at Saint Joseph's

Phase 3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Research Site

Phase 3

Anchorage, Alaska2 trials

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Anchorage Associates in Radiation Medicine

Phase 2

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Anchorage Associates in Radiation Medicine

Phase 3

Orange, California2 trials

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

University of California Irvine Medical Center

Phase 1

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Research Site

Phase 2

Tampa, Florida2 trials

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Moffitt Cancer Center ( Site 0261)

Phase 1

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Moffitt Cancer Center

Phase 2

Houston, Texas2 trials

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M D Anderson Cancer Center

Phase 1

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

MD Anderson Cancer Center

Phase 1

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Glendale, Arizona1 trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Palo Verde Hematology Oncology

Phase 3

Goodyear, Arizona1 trial

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

I-Mab Site 1016

Phase 2

Scottsdale, Arizona1 trial

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

HonorHealth Research Institute

Phase 1

Tucson, Arizona1 trial

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

Phase 1/2

Fayetteville, Arkansas1 trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Highlands Oncology Group

Phase 1

Fullerton, California1 trial

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Providence Medical Foundation

Phase 1/2

Los Angeles, California1 trial

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1

San Francisco, California1 trial

Venetoclax Basket Trial for High Risk Hematologic Malignancies

University of California San Francisco-Benioff Children's Hospital

Phase 1

Santa Monica, California1 trial

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

UCLA

Phase 2

Jacksonville, Florida1 trial

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Baptist MD Anderson Cancer Institute

Phase 3

Miami, Florida1 trial

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

University of Miami

Phase 1

Atlanta, Georgia1 trial

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

Emory University Hospital Midtown

Phase 2

Chicago, Illinois1 trial

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The University of Chicago

Phase 1

Boston, Massachusetts1 trial

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Massachusetts General Hospital

Phase 1

Grand Rapids, Michigan1 trial

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

START Midwest, LLC

Phase 1

Rochester, Minnesota1 trial

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Mayo Clinic in Rochester

Phase 2

Lake Success, New York1 trial

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

Chapel Hill, North Carolina1 trial

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Phase 2

Pittsburgh, Pennsylvania1 trial

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

UPMC Hillman Cancer Center ( Site 1904)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.